04 Jun 2020 --- Flavors and fragrances heavyweight Symrise has developed a cannabinoid that the company expects will “revolutionize the pharmaceutical market.” Coined Canapure, the nature-identical alternative to traditional cannabidiol (CBD) allows the pharmaceutical industry to access a synthetically produced CBD that is suitable both as an active pharmaceutical ingredient and as an intermediate product for the development of new substances. The product is based on D-limonene and achieves a purity level of 99.8 percent, according to Symrise.
